Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial

Journal of Clinical Psychopharmacology

Volumn 32, Issue 4, 2012, Pages 449-457

  Schreiner, Andreas ^a   Niehaus, Dana ^b   Shuriquie, Nasser Aldien ^c   Aadamsoo, Kaire ^d   Korcsog, Peter ^e   Salinas, Rolando ^f   Theodoropoulou, Pitsa ^g   Fernández, Lorena García ^h   Üçok, Alp ⁱ   Tessier, Christophe ^j   Bergmans, Paul ^k   Hoeben, Dagmar ^l  

^a JANSSEN CILAG GMBH   (Germany)

^b Flexivest Fourteen Research Centre   (South Africa)

^c Al Rashid Hospital   (Jordan)

^d North Estonian Regional Hospital   (Estonia)

^e Department of Psychiatry   (Slovakia)

^f Instituto Para la Prevención de Las Enfermedades Mentales   (Argentina)

^g SISMANOGLIO HOSPITAL   (Greece)

^h HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

ⁱ ISTANBUL UNIVERSITY   (Turkey)

^j Medical Affairs EMEA   (France)

^k Janssen Cilag BV Netherlands   (Netherlands)

^l Janssen Pharmaceutica NV   (Belgium)

more..

Author keywords

Body weight; Cholesterol; Olanzapine; Paliperidone ER; Triglyceride

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; HALOPERIDOL; LIPID; OLANZAPINE; PALIPERIDONE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSOMNIA; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MULTICENTER STUDY; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; ISOXAZOLES; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SCHIZOPHRENIA; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84863725402     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825cccad     Document Type: Article

References (56)

1. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
2. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
3. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100:20-38.
4. Tschoner A, Fleischhacker WW, Ebenbichler CF. Experimental antipsychotics and metabolic adverse effectsVfindings from clinical trials. Curr Opin Investig Drugs. 2009;10:1041-1048.
5. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol. 2006;16(suppl 3):S149YS155.
6. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13. (Pubitemid 46762118)
7. Kisely S, Cox M, Campbell LA, et al. An epidemiological study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients. Can J Psychiatry. 2009;54:269-274.
8. Newcomer JW. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. J Clin Psychiatry. 2009;70(suppl 3):30-36.
9. Newcomer JW, Ratner RE, Eriksson JW, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry. 2009;70:487-499.
10. Zyprexa (olanzapine). Prescribing information, June 2011. Lilly USA, LLC, Indianapolis, IN. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed September 1, 2011.
11. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28. (Pubitemid 40096067)
12. Smith RC, Lindenmayer JP, Davis JM, et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry. 2009;70:1501-1513.
13. Meyer JM, Rosenblatt LC, Kim E, et al. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry. 2009;70:318-325.
14. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59:1021-1026.
15. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65:510-517.
16. Cerit C, Vural M, Bos Gelmez SÜ, et al. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull. 2010;43:22-36.
17. Saddichha S, Manjunatha N, Ameen S, et al. Metabolic syndrome in first episode schizophreniaVa randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101:266-272.
18. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101:295-303.
19. Allison DB, Newcomer JW, Dunn AL, et al. Obesity among those with mental disorders. A National Institute of Mental Health meeting report. Am J Prev Med. 2009;36:341-350.
20. Weber NS, Cowan DN, Millikan AM, et al. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv. 2009;60:1059-1067.
21. Schorr SG, Slooff CJ, Bruggeman R, et al. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res. 2009;43:1106-1111.
22. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32. (Pubitemid 41587460)
23. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006;22:1879-1892. (Pubitemid 44663390)
24. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62:1363-1370. (Pubitemid 350180724)
25. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90:147-161. (Pubitemid 46178537)
26. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93:117-130. (Pubitemid 46817944)
27. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27:6-14. (Pubitemid 46105757)
28. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69:817-829. (Pubitemid 351838691)
29. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:218-226.
30. Turkoz I, Bossie CA, Lindenmayer JP, et al. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry. 2011;11:21.
31. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol. 2008;23:343-356.
32. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM Int J Med. 2007;100:395-404. (Pubitemid 47062891)
33. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007;68:1733-1740. (Pubitemid 350247503)
34. Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111:9-16.
35. Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol. 2011;31:154-159.
36. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802-809.
37. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888-4894. (Pubitemid 41159387)
38. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125-1132. (Pubitemid 41070972)
39. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14(suppl 8):S3YS28.
40. Arsenault BJ, Rana JS, Stroes ES. Beyond low-density lipoprotein cholesterol: respective contributions of nonYhigh-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55:35-41.
41. Bittner V, Johnson BD, Zineh I, et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J. 2009;157:548-555.
42. Hadaegh F, Khalili D, Ghasemi A, et al. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutr Metab Cardiovasc Dis. 2009;19:401-408.
43. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4:113-119.
44. Kozumplik O, Uzun S, Jakovljevi( M. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics. Psychiatr Danub. 2010;22:69-74.
45. Chwastiak LA, Rosenheck RA, McEvoy JP, et al. The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry. 2009;31:1-7.
46. Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol. 2011;51:631-638.
47. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:CD006654.
48. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69:274-285. (Pubitemid 351469271)
49. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23:649-659.
50. Hoffmann VP, Case M, Stauffer VL, et al. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder: post hoc analyses of 3 randomized, controlled clinical trials. J Clin Psychopharmacol. 2010;30:656-660.
51. Arango C, Gómez-Beneyto M, Brenlla J, et al. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Eur Neuropsychopharmacol. 2007;17:456-463. (Pubitemid 46509567)
52. Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with other oral antipsychotics. Eur Psychiatry. 2010;25(suppl 1):1107.
53. Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111-161. (Pubitemid 32108327)
54. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry. 1999;60(suppl 10):31-41. (Pubitemid 29237173)
55. Citrome L, Volavka J. Optimal dosing atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10:280-291.
56. Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3:869-897.